

# UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED

In re Application of: Donald L. Morton

Serial No.: 09/751,373

Filed: December 29, 2000

For: PLURIPOTENT VACCINE AGAINST

**ENVELOPED VIRUSES** 

AUG 2 9 2001

Group Art Unit: 1642

**TECH CENTER 1600/2900** 

Examiner: Unknown

Atty. Dkt. No.: JWCI:011USC1/SLH

#### CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the data below:

Auguat 24, 2001

Date

Steven L. Highlander

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/10027291/SLH.

This application is a continuation application of Serial No. 08/427,034 filed April 24,

1995 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule

37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously

cited by or submitted to the Patent and Trademark Office in prior application Serial No.

08/427,034.

Applicant respectfully requests that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

FULBRIGHT & JAWORSKI L.L.P. Attorney for Applicant 600 Congress Avenue, Suite 2400

Austin, Texas 78701 (512) 474-5201

Date:

August 24, 2001

Form	PTO-	1449	(modified)
------	------	------	------------

### Atty. Docket No. JWCI:011USC1/SLH

Serial No. 09/751,373

RECEIVED

**Applicant** 

**Donald Morton** 

AUG 2 9 2001

INFORMATION DISCLOSURE STATEMENT

List of Patents and Publications for Applicant's

(Use several sheets if necessary)

Filing Date: December 29, 2000 Group: 1642

TECH CENTER 1600/2900

**U.S. Patent Documents** 

**Foreign Patent Documents** 

Other Art

See Page 1

See Page 1

See Page 1

### **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 93/14126	07-22-93	PCT			
	B2	·WO 94/11016	05-26-94	PCT			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
	C1	Arthur <i>et al.</i> ,"Cellular Proteins Bound to Immunodeficiency Viruses: Implications for Pathogenesis and Vaccines", <i>Science</i> , 258:1935-1938, 1992.		
	C2	Chan et al., "Protection in Simian Immunodeficiency Virus-vaccinated Monkeys Correlates with Anti-HLA Class I Antibody Response", <i>Journal Exp. Medicine</i> , 176:1203-1207, October, 1992		
	C3	Clerici et al., "Circumvention of Defective CD4 T Helper Cell Function in HIV-Infected Individuals By Stimulation With HLA Alloantigens", <i>The Journal of Immunology</i> , 144(9):3266-3271, 1990.		
	C4	Cranage et al., "Species-Specific Responses to MHC Molecules in SIV Vaccination and Infection", Abstract No. 27, Symposium Nonhum. Primate Models Aids (US), 1993.		
	C5	Haynes, "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", <i>Science</i> , 260:1279-1286, 1993.		
	C6	Hoon et al., "Suppressor Cell Activity in a Randomized Trial of Pateints Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine and Low Dosages of Cyclophosphamide", Cancer Research, 50:5358-5364, 1990.		
	C7	Jones et al., "Prolonged Survival for Melanoma Patients With Elevated IgM Antibody to Oncofetal Antigen", JNCI, 66(2):249-254, 1981.		

25061892.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. JWCI:011USC1/SLH	Serial No. 09/751,373 RECEIVE
List of Patents and Publications for Applicant's	Applicant	
	Donald Morton	AUG 2 9 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date: December 29, 2000 Group: TECH CENTER 1600/2900

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents
See Page 1

Other Art See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Kion et al., "Anti-HIV and Anti-Anti-MHC Antibodies in Alloimmune and Autoimmune Mice", Science, 253:1138-1140, 1991.
	C9	Kiprov et al., "Alloimmunization to Prevent Aids?", Science, 263:737-738, 1994.
	C10	Langlois et al., "The Ability of Certain SIV Vaccines to Provoke Reactions Against Normal Cells", Sciences, 255:292-293, 1992.
	C11	Langlois et al., "Detection of Anti-Human Cell Antibodies in Sera from Macaques Immunized With Whole Inactivated Virus", Aids Research and Human Retroviruses, 8(9):1641-1652, 1992.
	C12	Morton et al., "Demonstration of Antibodies Against Human Malignant Melanoma By Immunofluorescence", Surgery, 64(1):233-240, 1968.
	C13	Morton et al., "Prolongation of Survival in Metastic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine", Annals of Surgery, 216(4):463-482, 1992.
	C14	Stott, E.J., "Anti-Cell Antibody in Macaques", Scientific Correspondence, 353:393, 1991.
	C15	Townsend, Alain, et al., "Antigen Recognition By Class I-Restricted T Lymphocytes", Annual Reviews Immunol, 7:601-624, 1989
	C16	Tsuji, Kimiyoshi, et al., "Proceedings of the Eleventh International Histocompatibility Workshop and Conference Held in Yokohama, Japan, 6-13 November, 1991", Oxford University Press, 1:10 1992.
-	C17	PCT Search Report mailed March 9, 1996.
	C18	Plaskin et al., "Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with NewCastle Disease virus (NDV)," Int. J. Cancer, 59:796-801.
	C19	Takahashi et al., "Induction of CD8+ cytotixuc T lymphocytes by immunization with syngeneic irradiated HIV-1 derived peptide-pulsed dendritic cells," International Immun., 5:849-857.
	C20	June et al., "The B7 and CD28 receptor families," Immun. Today, 15:321-331.
	C21	Wolf et al., "Expression and function of the emurine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells," PNAS., 89:4210-4214.
	C22	"Illustrated Dictionary of Immunology," edited by Julius Cruse et al., CRC Press, New York.

25061892.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Atty. Docket No. JWCI:011USC1/SLH  Applicant Donald Morton	Serial No. 09/751,373
nt's Applicant	09/751,373
• •	
Donald Morton	
NT	
Filing Date:	Group:
December 29, 2000	1642
reign Patent Documents	Other Art
See Page 1	See Page 1
	Filing Date: December 29, 2000 reign Patent Documents

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	"Fundamental Immunology," edited by William Paul. Raven Press, New York.

25061892.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.